The anti-PD-1/PD-L1 monoclonal antibody can block the binding of PD-L1 on the surface of tumor cells to T cell PD-1, relieve the suppression of tumor cell immune function, activate immune function, and thus kill tumor cells (41, 42). Here, CD274 is linked to neoplasm.